| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| R A Littrell, M Schneiderha. The neurobiology of schizophrenia. Pharmacotherapy. vol 16. issue 6 Pt 2. 1997-03-04. PMID:8947997. |
these findings are supported by the recent development of new, effective antipsychotic agents, such as clozapine and risperidone, whose actions are attributed to their combined serotonin and dopamine antagonism. |
1997-03-04 |
2023-08-12 |
Not clear |
| P Hertel, G G Nomikos, M Iurlo, T H Svensso. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology. vol 124. issue 1-2. 1997-01-29. PMID:8935802. |
risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. |
1997-01-29 |
2023-08-12 |
rat |
| P Hertel, G G Nomikos, M Iurlo, T H Svensso. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology. vol 124. issue 1-2. 1997-01-29. PMID:8935802. |
the antipsychotic drug risperidone shows high affinity for both central serotonin (5-ht)2a and dopamine (da)-d2 receptors in vivo. |
1997-01-29 |
2023-08-12 |
rat |
| J Gerlach, L Peacoc. New antipsychotics: the present status. International clinical psychopharmacology. vol 10 Suppl 3. 1996-12-13. PMID:8866764. |
according to this classification the new antipsychotics can be subdivided into three main categories: the relatively pure dopamine antagonists (d2 antagonists, including sulpiride and amisulpiride); the dopamine (d2)-serotonin (5-ht2)-norepinephrine (alpha 1) antagonists (risperidone, ziprazidone and sertindole); and the multireceptor antagonists (clozapine, olanzapine and seroquel). |
1996-12-13 |
2023-08-12 |
Not clear |
| J Gerlach, L Peacoc. New antipsychotics: the present status. International clinical psychopharmacology. vol 10 Suppl 3. 1996-12-13. PMID:8866764. |
new drugs such as olanzapine, seroquel and sertindole represent the further development of clozapine's positive qualities, while risperidone and ziprasidone are dominated to a greater extent by relatively traditional dopamine d2 receptor blockade. |
1996-12-13 |
2023-08-12 |
Not clear |
| B Gallhofer, U Bauer, S Lis, S Krieger, H Grupp. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 6 Suppl 2. 1996-12-04. PMID:8792116. |
maze tests were used to determine the effects on cognition of conventional dopamine antagonist neuroleptics (haloperidol and fluphenazine) and the newer serotonin-dopamine antagonist antipsychotics (risperidone and clozapine). |
1996-12-04 |
2023-08-12 |
Not clear |
| G B Varty, G A Higgin. Reversal of dizocilpine-induced disruption of prepulse inhibition of an acoustic startle response by the 5-HT2 receptor antagonist ketanserin. European journal of pharmacology. vol 287. issue 2. 1996-10-24. PMID:8749037. |
in recent study, we found that the potent d2/5-ht2 receptor antagonist, risperidone, but not the selective dopamine d2 receptor antagonist, raclopride, could reverse this disruption. |
1996-10-24 |
2023-08-12 |
Not clear |
| D Giardinà, M Crucianelli, C Melchiorre, C Taddei, R Test. Receptor binding profile of cyclazosin, a new alpha 1B-adrenoceptor antagonist. European journal of pharmacology. vol 287. issue 1. 1996-08-07. PMID:8666020. |
the binding profile of cyclazosin, a new prazosin-related alpha 1-adrenoceptor antagonist, at alpha 1-, alpha 2-adrenoceptors, dopamine d2 and 5-ht1a receptors was compared to that of 5-methylurapidil, spiperone, risperidone and other prazosin-related ligands. |
1996-08-07 |
2023-08-12 |
Not clear |
| S Kapur, G Remingto. Serotonin-dopamine interaction and its relevance to schizophrenia. The American journal of psychiatry. vol 153. issue 4. 1996-04-24. PMID:8599393. |
the therapeutic success of clozapine and risperidone has focused attention on the interaction between serotonin and dopamine systems as an avenue for superior therapeutics in schizophrenia. |
1996-04-24 |
2023-08-12 |
Not clear |
| W Wan, D J Ennulat, B M Cohe. Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain. Brain research. vol 688. issue 1-2. 1996-02-14. PMID:8542328. |
administration of single doses of a wide range of typical neuroleptic antipsychotic drugs (including the potent dopamine d2 antagonist haloperidol and the mixed monoamine antagonist chlorpromazine) and atypical antipsychotic drugs (including the weak dopamine d2 antagonists clozapine and thioridazine, the relatively pure d2 antagonist raclopride and the mixed d2 and serotonin s2 antagonist risperidone). |
1996-02-14 |
2023-08-12 |
rat |
| M Didrikse. Effects of antipsychotics on cognitive behaviour in rats using the delayed non-match to position paradigm. European journal of pharmacology. vol 281. issue 3. 1996-01-25. PMID:8521906. |
the acute effects of the dopamine d1 receptor antagonist sch 23390 [(r)-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1h-3-benzazepi n-7-ol d hemimaleat, the dopamine d2 receptor antagonists raclopride and haloperidol, the compounds with mixed receptor profiles clozapine, risperidone and sertindole, the alpha 1-adrenoceptor antagonist prazosin and scopolamine were investigated in a delay-response task, a test for working memory, for rats. |
1996-01-25 |
2023-08-12 |
rat |
| T Skarsfeld. Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. European journal of pharmacology. vol 281. issue 3. 1996-01-25. PMID:8521912. |
risperidone, olanzapine, seroquel, ziprasidone and amperozide) were given daily for 21 days to rats and the effect on the number of spontaneously active dopamine neurons in ventral tegmental area and substantia nigra pars compacta was determined. |
1996-01-25 |
2023-08-12 |
rat |
| T Skarsfeld. Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. European journal of pharmacology. vol 281. issue 3. 1996-01-25. PMID:8521912. |
risperidone, olanzapine and amperozide showed some selectivity (at one particular dose) for decreasing the number of active dopamine neurons in the ventral tegmental area. |
1996-01-25 |
2023-08-12 |
rat |
| J Arn. Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. European journal of pharmacology. vol 283. issue 1-3. 1996-01-18. PMID:7498321. |
classical antipsychotics (haloperidol, fluphenazine and cis(z)-flupentixol) and the selective dopamine d2 receptor antagonist remoxipride inhibit hypermotility in the two conditions with similar potencies, whereas sertindole, clozapine, risperidone, ziprasidone and olanzapine preferentially inhibit the effect of the low dose of d-amphetamine (selectivity ratios between 6.5 and 18). |
1996-01-18 |
2023-08-12 |
Not clear |
| S Nyberg, M L Dahl, C Halldi. A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. Psychopharmacology. vol 119. issue 3. 1995-10-18. PMID:7545821. |
we have previously examined central d2 dopamine and 5-ht2 receptor occupancy after 1 mg risperidone orally in three healthy subjects who were extensive metabolizers (em) of debrisoquin, using positron emission tomography and the radioligands [11c]raclopride and [11c]nmsp. |
1995-10-18 |
2023-08-12 |
human |
| H He, J S Richardso. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. International clinical psychopharmacology. vol 10. issue 1. 1995-08-30. PMID:7542676. |
a pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-ht2 and dopamine d2 receptors. |
1995-08-30 |
2023-08-12 |
human |
| L Farde, S Nyberg, G Oxenstierna, Y Nakashima, C Halldin, B Ericsso. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. Journal of clinical psychopharmacology. vol 15. issue 1 Suppl 1. 1995-05-31. PMID:7537284. |
risperidone is, accordingly, a suitable drug for the examination of the clinical benefit of combined serotonin and dopamine antagonism. |
1995-05-31 |
2023-08-12 |
Not clear |
| G F Busatto, L S Pilowsky, D C Costa, P J Ell, N P Verhoeff, R W Kerwi. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study. Psychopharmacology. vol 117. issue 1. 1995-05-25. PMID:7536945. |
dopamine d2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123i-ibzm single photon emission tomography (spet) study. |
1995-05-25 |
2023-08-12 |
human |
| D Keega. Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 39. issue 9 Suppl 2. 1995-04-06. PMID:7533051. |
risperidone, a novel antipsychotic with high binding affinity for serotonin 5-ht2 and a lesser affinity for dopamine d2 receptors, is described and clinical studies are reviewed. |
1995-04-06 |
2023-08-12 |
Not clear |
| K Kitaichi, K Yamada, T Hasegawa, H Furukawa, T Nabeshim. Effects of risperidone on phencyclidine-induced behaviors: comparison with haloperidol and ritanserin. Japanese journal of pharmacology. vol 66. issue 2. 1995-03-29. PMID:7532732. |
neurochemically, the increasing effects of risperidone on the content of dopac and the ratio of dopac to dopamine in the striatum were lower than those of haloperidol. |
1995-03-29 |
2023-08-12 |
rat |